All Stories

  1. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety
  2. Uncovering the Risk of Inhalational Exposures Across Interstitial Lung Diseases
  3. Prognostic accuracy of a peripheral blood transcriptome signature in chronic hypersensitivity pneumonitis
  4. Diagnosis and Evaluation of Hypersensitivity Pneumonitis: CHEST Guideline and Expert Panel Report − Executive Summary
  5. Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
  6. Exposure Assessment Tools for Hypersensitivity Pneumonitis. An Official American Thoracic Society Workshop Report
  7. In-hospital mortality trends among patients with idiopathic pulmonary fibrosis in the United States between 2013-2017: a comparison of academic and non-academic programs
  8. Duration of rheumatoid arthritis and the risk of developing interstitial lung disease
  9. Age-associated B Cells Appear in Patients with Granulomatous Lung Diseases
  10. Soldiering on the Job When Ill: Productivity Costs in Connective Tissue Disease–associated Interstitial Lung Disease
  11. IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis
  12. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
  13. Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA
  14. Clinical Decision-Making in Hypersensitivity Pneumonitis: Diagnosis and Management
  15. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
  16. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
  17. Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis-Related Mortality in the United States, 1999 to 2017
  18. Reply to Hall et al.: Hypersensitivity Pneumonitis Mortality by Industry and Occupation
  19. Increasing Hypersensitivity Pneumonitis–related Mortality in the United States from 1988 to 2016
  20. The Role of Computed Tomography Honeycombing in Profiling Disease Progression in Chronic Interstitial Lung Disease
  21. Changing trends in age-adjusted pulmonary fibrosis mortality in the USA: a joinpoint regression analysis
  22. United States trends in mortality rates for primary immunodeficiency diseases
  23. IPF Look-Alikes
  24. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype
  25. Diagnostic Decision-Making in Hypersensitivity Pneumonitis: Toward a Consensus Statement
  26. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey
  27. Epidemiology of Hypersensitivity Pneumonitis among an Insured Population in the United States: A Claims-based Cohort Analysis
  28. An educational initiative to improve the team-based care of patients with idiopathic pulmonary fibrosis
  29. Presence of Air Trapping and Mosaic Attenuation on Chest Computed Tomography Predicts Survival in Chronic Hypersensitivity Pneumonitis
  30. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis
  31. Refining the Burden of Idiopathic Pulmonary Fibrosis: The Cocktail Party Effect
  32. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival
  33. Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease
  34. Current Approach to Diagnosis and Management of Pulmonary Eosinophilic Syndromes: Eosinophilic Pneumonias, Eosinophilic Granulomatosis with Polyangiitis, and Hypereosinophilic Syndrome
  35. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
  36. Inflammatory Leukocyte Phenotypes Correlate with Disease Progression in Idiopathic Pulmonary Fibrosis
  37. Fibrotic hypersensitivity pneumonitis
  38. Pulmonary Function and Survival in Idiopathic vs Secondary Usual Interstitial Pneumonia
  39. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study
  40. Nonasthmatic Eosinophilic Bronchitis
  41. Bronchiectasis
  42. Eosinophilic Lung Diseases
  43. Identifying an Inciting Antigen Is Associated With Improved Survival in Patients With Chronic Hypersensitivity Pneumonitis
  44. FEV1 over time in patients with connective tissue disease-related bronchiolitis
  45. Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease
  46. Granulomatous Lymphocytic Interstitial Lung Disease
  47. Peeling away the layers of the volume-outcome effect and harvesting hidden connections*
  48. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease
  49. Obstructive sleep apnea does not promote esophageal reflux in fibrosing interstitial lung disease
  50. Rheumatoid Arthritis and Pneumoconiosis
  51. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death
  52. Air hunger, unwelcome guests, clogged pipes and idiopathic inflammatory myositis: Can we do better?
  53. Interpretation of airway pressure waveforms
  54. Eosinophilic Lung Diseases
  55. Increased Risk of Pulmonary Embolism Among US Decedents With Sarcoidosis From 1988 to 2007
  56. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease
  57. Derivation and Diagnostic Accuracy of the Surgical Lung Injury Prediction Model
  58. Sarcoidosis-related Mortality in the United States from 1988 to 2007
  59. Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
  60. Rheumatoid Arthritis–Interstitial Lung Disease–associated Mortality
  61. Long-Term Survival and Quality of Life After Transfusion-Associated Pulmonary Edema in Critically III Medical Patients
  62. Severity of Illness and Outcome in Patients With End-Stage Idiopathic Pulmonary Fibrosis Requiring Mechanical Ventilation: Response
  63. Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis
  64. Outcome of critically ill patients with influenza virus infection
  65. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia
  66. Heart Rate Recovery After 6-Min Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis
  67. Intraoperative ventilator settings and acute lung injury after elective surgery: a nested case control study
  68. Respiratory Monitoring
  69. Interpretation of airway pressure waveforms
  70. Ventilator Settings and Outcome of Respiratory Failure in Chronic Interstitial Lung Disease
  71. The Practice of Platelet Transfusion in the Intensive Care Unit
  72. The addition of decision support into computerized physician order entry reduces red blood cell transfusion resource utilization in the intensive care unit
  73. Nonfamilial hemophagocytic lymphohistiocytosis
  74. Post-thoracentesis trapped lung
  75. Acute pancreatitis due to hereditary angioedema
  76. Transfusion‐related acute lung injury and pulmonary edema in critically ill patients: a retrospective study
  77. Intraoperative Tidal Volume as a Risk Factor for Respiratory Failure after Pneumonectomy
  78. A case of hydrocortisone desensitization in a patient with radiocontrast-induced anaphylactoid reaction and corticosteroid allergy
  79. Interpretation of airway pressure waveforms
  80. Sepsis during pregnancy
  81. Interpretation of airway pressure waveforms